USP28 deletion and small molecule inhibition destabilises c-Myc and elicits regression of squamous cell lung carcinoma

E. Josue Ruiz, Adán Pinto-Fernández, A.p. Turnbull, Linxiang Lan, Thomas M. Charlton, Hannah C. Scott, Andreas Damianou, George Vere, Eva M. Riising, Clive Da Costa, Wojciech Krajewski, David J. Guerin, Jeffrey D. Kearns, Stephanos Ioannidis, Marie Katz, Crystal McKinnon, Jonathan C. O’Connell, Natalia Moncaut, Ian Rosewell, Emma Nye, Neil P. Jones, Claire Heride, Malte Gersch, Min Wu, Christopher J. Dinsmore, Tim Hammonds, Sunkyu Kim, David Komander, Sylvie Urbé, Michael J. Clague, Benedikt M. Kessler, Axel BehrensbioRxiv 2020 · DOI

TL;DR

This paper identifies USP28, a deubiquitinating enzyme, as a critical driver for the maintenance and progression of lung squamous cell carcinoma (LSCC). By developing a selective small molecule inhibitor (FT206), the researchers demonstrate that targeting USP28 effectively reduces LSCC tumor growth and induces regression in both mouse models and human xenografts, offering a promising new therapeutic avenue for this challenging cancer.

What Problem Does This Paper Address?

Lung squamous cell carcinoma (LSCC) is a deadly cancer with limited treatment options and a dismal 5-year survival rate. While targeted therapies have revolutionized the treatment of other lung cancer subtypes like lung adenocarcinoma (LADC), LSCC has lagged behind. This paper addresses the urgent need for novel therapeutic targets and effective treatments for LSCC. Specifically, it investigates the role of USP28, an enzyme known to stabilize oncoproteins like c-MYC, in LSCC tumorigenesis and explores its potential as a drug target.

Methods

The researchers employed a multi-pronged approach:

  • Genetic Inactivation: They used genetically engineered mouse models (GEMMs) to study the effects of deleting the Usp28 gene in established LSCC tumors. This involved sophisticated Cre-loxP and Flp-FRT systems for temporal and spatial control of gene deletion.
  • Small Molecule Inhibition: A novel, selective small molecule inhibitor of USP28, named FT206, was developed and characterized. Its potency and selectivity were assessed using activity-based protein profiling (ABPP) and quantitative mass spectrometry.
  • In Vitro and In Vivo Assays: The efficacy of FT206 was tested in LSCC cell lines (measuring cell proliferation and protein levels) and in various mouse models, including autochthonous LSCC tumors and human LSCC xenografts.
  • Immunohistochemistry and Western Blotting: These standard molecular biology techniques were used extensively to assess protein levels (e.g., c-Myc, c-Jun, Δp63, USP28) and cellular markers in tumor tissues and cell lysates.
  • Genomic Data Analysis: Publicly available cancer genomics data (TCGA) was analyzed to investigate the frequency of genetic alterations in USP28 and FBXW7 in human LSCC.

Datasets

  • TCGA (The Cancer Genome Atlas): Used for analyzing genetic alterations (mutations, copy-number alterations) and mRNA expression of USP28 and FBXW7 in human LSCC samples.
  • Cordoba Biobank: Provided human lung tissue samples (normal and LSCC) for mRNA expression analysis by RT-PCR.
  • Publicly available datasets: Utilized for analyzing USP28 expression in human LSCC.

Key Insights and Ideas

  • USP28 is a critical Achilles' heel for LSCC: Unlike its role in other cancers or normal physiology, USP28 appears to be essential for the maintenance and progression of LSCC tumors. This specificity is key for therapeutic targeting.
  • Targeting USP28 destabilizes c-Myc and other oncoproteins: USP28's primary function in this context is to deubiquitinate and stabilize c-Myc, c-Jun, and Δp63. Inhibiting USP28 leads to the degradation of these proteins, effectively shutting down key oncogenic pathways in LSCC.
  • A highly selective inhibitor is achievable: The development of FT206 demonstrates that it's possible to create small molecules that potently inhibit USP28 with minimal off-target effects on other deubiquitinases, including its close homolog USP25.
  • Genetic deletion and pharmacological inhibition yield similar results: The fact that both genetic inactivation of Usp28 and treatment with FT206 lead to LSCC regression strongly supports USP28 as the direct target responsible for the observed effects.
  • LSCC is uniquely dependent on USP28: The study highlights that LSCC tumors are more reliant on USP28 and its substrates (c-Myc, c-Jun, Δp63) compared to LADC, suggesting a potential for differential therapeutic response.

Key Results

  • Genetic inactivation of Usp28: Led to dramatic regression of established murine LSCC tumors.
  • Development of FT206: A small molecule inhibitor of USP28 with nanomolar potency and high selectivity.
  • FT206 treatment:
    • Induced substantial regression of autochthonous murine LSCC tumors and human LSCC xenografts.
  • Significantly reduced LSCC tumor number (by 68%) and size (by over 45%).
  • Caused a dramatic decrease in c-Myc protein levels in LSCC cells and tumors.
  • Induced apoptotic cell death in LSCC cells.
  • Was well-tolerated in mice, with no noticeable adverse effects.
  • Genomic analysis: Revealed that 25% of human LSCC cases show gain-of-function alterations in USP28.
  • Human xenografts: FT206 treatment significantly impaired the growth of human LSCC xenografts, accompanied by a reduction in c-Myc levels.

Limitations and Future Work

  • Off-target effects: While FT206 shows high selectivity, the authors acknowledge that inhibition of USP25 and potential additional off-target effects might contribute to the observed phenotype. Further studies could explore these in more detail.
  • LADC response: The study found that USP28 inhibition had a modest effect on LADC tumors, suggesting LSCC's unique dependence on USP28 and its substrates. Future work could delve deeper into the molecular mechanisms underlying this differential sensitivity.
  • Clinical translation: The promising results in preclinical models warrant further investigation and clinical trials to evaluate USP28 inhibition as a therapeutic option for LSCC patients.

Summary updated

Abstract

Abstract Lung squamous cell carcinoma (LSCC) is a considerable global health burden, with an incidence of over 600,000 cases per year. Treatment options are limited, and patient 5-year survival rate is less than 5%. The ubiquitin specific protease 28 (USP28) has been implicated in tumorigenesis through its stabilization of the oncoprotein c-MYC. Here, we show that genetic inactivation of Usp28 induced regression of established murine LSCC lung tumors. We developed a small molecule that inhibits USP28 activity in the low nanomole range. While displaying cross-reactivity against the closest homologue USP25, this inhibitor showed a high degree of selectivity over other deubiquitinases. USP28 inhibitor treatment resulted in a dramatic decrease in c-Myc proteins levels and consequently induced substantial regression of autochthonous murine LSCC tumors and human LSCC xenografts, thereby phenocopying the effect observed by genetic deletion. Thus, USP28 may represent a promising therapeutic target for the treatment of squamous cell lung carcinoma.
BibTeX
@misc{ruiz2020usp,
  author = {E. Josue Ruiz and Adán Pinto-Fernández and A.P. Turnbull and Linxiang Lan and Thomas M. Charlton and Hannah C. Scott and Andreas Damianou and George Vere and Eva M. Riising and Clive Da Costa and Wojciech Krajewski and David J. Guerin and Jeffrey D. Kearns and Stephanos Ioannidis and Marie Katz and Crystal McKinnon and Jonathan C. O’Connell and Natalia Moncaut and Ian Rosewell and Emma Nye and Neil P. Jones and Claire Heride and Malte Gersch and Min Wu and Christopher J. Dinsmore and Tim Hammonds and Sunkyu Kim and David Komander and Sylvie Urbé and Michael J. Clague and Benedikt M. Kessler and Axel Behrens},
  title = {{USP28 deletion and small molecule inhibition destabilises c-Myc and elicits regression of squamous cell lung carcinoma}},
  year = {2020},
  doi = {10.1101/2020.11.17.377705},
  howpublished = {bioRxiv},
}
Figure